AR049141A1 - Uso de imatinib para tratar trastornos hepaticos e infecciones virales - Google Patents

Uso de imatinib para tratar trastornos hepaticos e infecciones virales

Info

Publication number
AR049141A1
AR049141A1 ARP050102296A ARP050102296A AR049141A1 AR 049141 A1 AR049141 A1 AR 049141A1 AR P050102296 A ARP050102296 A AR P050102296A AR P050102296 A ARP050102296 A AR P050102296A AR 049141 A1 AR049141 A1 AR 049141A1
Authority
AR
Argentina
Prior art keywords
virus
imatinib
viral infections
hepatic disorders
treat hepatic
Prior art date
Application number
ARP050102296A
Other languages
English (en)
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049141(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of AR049141A1 publication Critical patent/AR049141A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de imatinib para tratar enfermedades hepáticas virales y en particular, para la hepatitis viral. Proporciona el uso de imatinib pra inhibir la replicacion, transmision o ambas de virus de la hepatitis. Se refiere además al uso de imatinib para inhibir la replicacion, transmision o ambas de otros virus incluyendo virus de herpes, poxvirus, virus influenza, virus parainfluenza, virus respiratorio sincitial, rinovirus, virus de la fiebre amarilla, virus del Nilo occidental, y virus de la encefalitis.
ARP050102296A 2004-06-04 2005-06-06 Uso de imatinib para tratar trastornos hepaticos e infecciones virales AR049141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57657304P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
AR049141A1 true AR049141A1 (es) 2006-06-28

Family

ID=35462722

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102296A AR049141A1 (es) 2004-06-04 2005-06-06 Uso de imatinib para tratar trastornos hepaticos e infecciones virales

Country Status (25)

Country Link
US (1) US8293745B2 (es)
EP (1) EP1750713B1 (es)
JP (1) JP5015769B2 (es)
KR (1) KR101246863B1 (es)
CN (2) CN102085202A (es)
AP (1) AP2715A (es)
AR (1) AR049141A1 (es)
AU (1) AU2005249159A1 (es)
BR (1) BRPI0511805A (es)
CA (1) CA2568671A1 (es)
DK (1) DK1750713T3 (es)
EA (1) EA013813B1 (es)
EC (1) ECSP055833A (es)
ES (1) ES2397830T3 (es)
IL (1) IL179796A0 (es)
MA (1) MA28840B1 (es)
MX (1) MXPA06014063A (es)
MY (1) MY148676A (es)
PE (1) PE20060399A1 (es)
PL (1) PL1750713T3 (es)
PT (1) PT1750713E (es)
TN (1) TNSN06398A1 (es)
TW (1) TWI393565B (es)
UY (1) UY28942A1 (es)
WO (1) WO2005117885A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725295B1 (en) 2004-01-21 2010-09-15 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
AU2006316823A1 (en) 2005-11-25 2007-05-31 Novartis Ag F,G,H,I and K crystal forms of imatinib mesylate
JP5520479B2 (ja) 2006-02-20 2014-06-11 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、白色発光素子、及び照明装置
JP5616063B2 (ja) * 2006-10-04 2014-10-29 ヤンセン・アールアンドデイ・アイルランド Ｈｃｖ阻害剤として有用なカルボキシアミド４−［（４−ピリジル）アミノ］ピリミジン
WO2009021150A2 (en) 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
EP2334379A2 (en) * 2008-09-26 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
AU2009344851A1 (en) * 2008-12-19 2011-06-23 The Regents Of The University Of California Use of epidermal growth factor inhibitors in the treatment of viral infection
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
WO2013024158A1 (en) * 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
EP2903979B1 (en) * 2012-10-04 2020-08-19 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
WO2017083971A1 (en) * 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
CN111481671A (zh) * 2020-05-26 2020-08-04 华中科技大学同济医学院附属协和医院 酪氨酸激酶抑制剂在制备系统性红斑狼疮脑病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443965A (en) * 1990-04-06 1995-08-22 Genelabs Incorporated Hepatitis C virus epitopes
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US20030191048A1 (en) * 2000-08-01 2003-10-09 Mattias Luukkonen Gene expression profile for KSHV infection and methods for treating same
JP4316893B2 (ja) * 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
GB2398781B (en) * 2002-05-23 2005-02-02 Cytopia Pty Ltd Kinase inhibitors
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
EP1725295B1 (en) * 2004-01-21 2010-09-15 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection

Also Published As

Publication number Publication date
TW200602059A (en) 2006-01-16
EP1750713B1 (en) 2012-10-17
MY148676A (en) 2013-05-31
TNSN06398A1 (en) 2008-02-22
MA28840B1 (fr) 2007-09-03
DK1750713T3 (da) 2013-02-11
BRPI0511805A (pt) 2008-01-15
CN102085202A (zh) 2011-06-08
JP5015769B2 (ja) 2012-08-29
PE20060399A1 (es) 2006-07-06
UY28942A1 (es) 2005-11-30
KR20070051832A (ko) 2007-05-18
AP2006003863A0 (en) 2006-12-31
CN1976709A (zh) 2007-06-06
JP2008501646A (ja) 2008-01-24
IL179796A0 (en) 2007-05-15
WO2005117885A1 (en) 2005-12-15
CA2568671A1 (en) 2005-12-15
EP1750713A1 (en) 2007-02-14
KR101246863B1 (ko) 2013-03-25
EA013813B1 (ru) 2010-08-30
ES2397830T3 (es) 2013-03-11
EA200602289A1 (ru) 2007-04-27
EP1750713A4 (en) 2010-09-15
MXPA06014063A (es) 2007-04-25
US8293745B2 (en) 2012-10-23
AU2005249159A1 (en) 2005-12-15
AP2715A (en) 2013-07-31
PT1750713E (pt) 2013-01-25
PL1750713T3 (pl) 2013-04-30
TWI393565B (zh) 2013-04-21
ECSP055833A (es) 2005-09-20
US20060275260A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
AR049141A1 (es) Uso de imatinib para tratar trastornos hepaticos e infecciones virales
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
ECSP13010937A (es) Compuestos antivirales
ECSP11011292A (es) Combinación de un inhibidor de nucleósido polimerasa con un inhibidor de proteasa macrocíclica y su uso en el tratamiento de hepatitis c, fibrosis hepática y función hepática alterada
CO6761348A2 (es) Compuestos antivirales
ECSP10010004A (es) Derivados de indol 2-carboxi sustituidos y métodos para su utilización
ECSP077252A (es) Métodos para tratar la hepatitis C
WO2009136979A3 (en) Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
AR057623A1 (es) Materiales y metodos para el tratamiento de las infecciones virales
CL2015003117A1 (es) Modificaciones en la estructura cristalina
BRPI0513196A (pt) formulações tópicas antivirais
CL2010001407A1 (es) Compuestos derivados de purina y pirimidina sustituidos; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades virales tales como hepatitis c, dengue, fiebre amarilla, polio, hepatitis a, entre otras.
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
CU23781B7 (es) Compuestos y métodos para inhibir la replicación de hepatitis c viral
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
NO20091258L (no) Entantiomerisk rene fosfoindoler as HIV inhibitorer
DK1824563T3 (da) Sammensætninger, der omfatter ornithin og phenylacetat eller phenylbutyrat til behandling af hepatisk encephalopati
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
CL2011002286A1 (es) Uso de compuestos derivados de nucleosidos para tratar una enfermedad viral; compuestos derivados de nucleosidos; y composicion farmaceutica que comprende los compuestos.
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
WO2014039987A3 (en) Treatment of disease using inter-alpha inhibitor proteins
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
CL2004000261A1 (es) Procedimiento para la eliminacion de virus en soluciones de fibrinogeno de aplicacion terapeutica.
RS52377B (en) Administration of thymosin 1, alone or in combination with PTX3 or ganciclovir, for the treatment of CITOMEGALOVIRUS INFECTION